Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 2
Abstract
From the 47 Swiss EPP-patients treated at our center since 2006, we included those 38 patients in the current analysis who received at least one afamelanotide dose between 2016 and 2018 and underwent regular laboratory testing before and during the treatment. We compared the means of pretreatment measurements with those during the treatment. Protoporphyrin concentrations dropped from 21.39 ± 11.12 (mean ± SD) before afamelanotide to 16.83 ± 8.24 µmol/L (p < .0001) during treatment. Aspartate aminotransferase decreased from 26.67 ± 13.16 to 22.9 ± 7.76 IU/L (p = .0146). For both entities, patients with higher values showed a more progressive decrease, indicating a risk reduction of EPP-related liver disease. The pre-existing hypochromia and broad mean red-cell distribution width were further augmented under afamelanotide. This was more likely due to an influence of afamelanotide on maturating erythroblasts than due to an exacerbated iron deficiency, as mean zinc-protoporphyrin decreased significantly and ferritin remained unchanged. No serious afamelanotide-related adverse events were observed for a total of 240 treatment years. Our findings point to a protective effect of afamelanotide on erythroblast maturation and protoporphyrin-induced liver injury. Afamelanotide, a skin tanning hormone, may protect patients with erythropoietic protoporphyria not only from skin burns, but also from liver injury associated with the disease. Patients with erythropoietic protoporphyria (EPP), an inherited metabolic disease, suffer from light-induced skin burns and liver injury elicited by the accumulated light sensitizer protoporphyrin. The excess protoporphyrin is produced in red cell precursors in the bone marrow, and it is eliminated from the body via the liver and bile. A high protoporphyrin excretion burden damages the liver cells, the risk for this increases with higher protoporphyrin concentrations. About 20% of EPP patients show some sign of liver injury and 4% develop life-threatening liver dysfunction. Afamelanotide, closely related to natural α-melanocyte stimulating hormone (MSH), induces skin tanning. This effect protects EPP patients from light-induced skin burns as shown in previous studies. We have treated Swiss EPP patients with afamelanotide since 2006, and we regularly perform safety tests of this treatment. Recent in vitro and animal studies demonstrated α-MSH effects other than skin tanning, including an improved synthesis of red blood cell precursors in the bone-marrow and protection of the liver from experimentally induced damage. Until now, it is unknown whether afamelanotide has similar effects in the human organism. To study this question, we analyzed retrospectively the safety laboratory data of 38 Swiss patients, who received at least one dose of afamelanotide from 2016 to 2019. We found that both, the average protoporphyrin concentrations and aspartate aminotransferase, a test for liver function, improved during afamelanotide treatment as compared to before. We concluded that afamelanotide applied to EPP patients to protect them from light-induced skin burns also may reduce their risk of liver injury.Keywords
Funding Information
- Stiftung für wissenschaftliche Forschung am Stadtspital Triemli (Not available)
This publication has 47 references indexed in Scilit:
- Melanocortin receptors in rat liver cells: change of gene expression and intracellular localization during acute-phase responseHistochemistry and Cell Biology, 2011
- Structure, function and regulation of the melanocortin receptorsEuropean Journal of Pharmacology, 2011
- Liver disease and erythropoietic protoporphyria: A concise reviewWorld Journal of Gastroenterology, 2010
- Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1Blood, 2008
- C-Terminal Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-linked Dominant Protoporphyria without Anemia or Iron OverloadThe American Journal of Human Genetics, 2008
- Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyriaBlood, 2007
- Regulation of protein synthesis by the heme-regulated eIF2α kinase: relevance to anemiasBlood, 2006
- α‐Melanocyte‐stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in miceThe Journal of Gene Medicine, 2006
- Mechanisms of photosensitivity in porphyric patients with special emphasis on erythropoietic protoporphyriaJournal of Photochemistry and Photobiology B: Biology, 1991
- Protoporphyrin-induced Cholestasis in the Isolated In Situ Perfused Rat LiverJournal of Clinical Investigation, 1981